๐๏ธ Verified NIH Record โข Updated 2026-03-26
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer (NCT00859781)
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
๐ต Active, Not Recruiting Phase2 ๐ Investigational Drug / Biologic Sponsor: Weill Medical College of Cornell University
๐ฉบ Plain-English Summary (8th-Grade Level)
The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591 in combination with ketoconazole and hydrocortisone against prostate cancer.
Who can join: Review the eligibility criteria below.
Location: Cedars Sinai โ Los Angeles, California
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (9 Sites)
- Cedars Sinai โ Los Angeles, California
- USC/Norris Comprehensive cancer center โ Los Angeles, California
- Georgetown University Medical Center โ Washington D.C., District of Columbia
- Indiana University Melvin and Bren Simon Cancer Center โ Indianapolis, Indiana
- University of Iowa Hospitals and Clinics โ Iowa City, Iowa
- The University of Kansas Cancer Center โ Westwood, Kansas
- Weill Cornell Medical College โ New York, New York
- UPMC Hillman Cancer Center โ Pittsburgh, Pennsylvania
- University of Utah โ Salt Lake City, Utah
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC โ Homewood, Alabama
- A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described โ Homewood, Alabama
- Stereotactic Ablative Radiation Therapy for Prostate Cancer โ Charleston, South Carolina
- A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer โ Basking Ridge, New Jersey
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer โ Phoenix, Arizona
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer โ Baltimore, Maryland
Explore by condition: All Prostate Cancer clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.